Patent attorney Jay Halt explains how medtech companies should align IP strategy with FDA compliance to avoid unenforceable patents and regulatory issues.
MarketBeat on MSN
Quest Diagnostics Q2 earnings call highlights
Myriad Genetics Sees Stock Surge with Hereditary Cancer Tests Quest Diagnostics (NYSE:DGX) reported double-digit revenue ...
Australia has slipped behind countries including the United States, Thailand and Serbia in a major global women’s health ...
Quest Diagnostics (NYSE:DGX) reported second-quarter financial results on Thursday. The transcript from the company's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results